Western Acq Ventures Stock (NASDAQ: WAVS)

Western Acq Ventures (NASDAQ:WAVS) Stock, Quote.Headers.trade-ideas

Western Acquisition Ventures Corp is a blank check company.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABOS

ALNY

APLS

ARDS

ARGX

AWIN

BBIO

BCAN

BLBX

CJET

CNSL

CVGW

EVGN

EVGO

FTCH

FYBR

GBNH

GNPX

HCTI

JZXN

KSCP

LIXT

MNPR

NOVN

NVFY

PRDS

PRFX

PUYI

RKDA

RMTI

STGW

SXTP

TIVC

UPST

UTME

UTRS

VIRI

VRAY

WAVS

YELP

ZIMV

ZLAB

Gainers


	ProMIS Neurosciences, Inc.  (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer&#39;s Association International Conference 2023 on computationally-derived antibody and vaccine from Alzheimer&#39;s pipeline.


Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Pre-Market Outlook

BAOS

CVKD

EBIX

EGIO

FREQ

NVVE

Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket

ACAD

AEHR

AIMD

AMBO

ARBB

ARCT

AULT

BDRX

BENF

CMAX

COMM

CRBU

EDTX

EFSH

ELAN

ERIC

EVTV

FNKO

GLMD

GOEV

GTBP

HAYW

INGN

LESL

LGHL

LILM

LITE

LUMN

LUNR

NKLA

NTRB

OPRA

QBTS

SFWL

THRX

TIXT

VINE

Gainers


	PainReform Ltd. (NASDAQ: PRFX) shares climbed 103% to $11.67. PainReform recently announced pricing of a $2.7 million concurrent registered direct offering and private placement.


Why State Street Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Western Acquisition Ventures Corp. - Common Stock

Western Acquisition Ventures Corp

Western Acquisition Ventures Corp. - Unit

Western Acquisition Ventures Corp. - Warrant

Under this agreement, the counterparty will procure renewable energy from a Recurrent Energy solar PV project located in Valladolid, in the northwestern Spanish autonomous community of Castilla y León.

CSIQ

Recurrent Energy Signs 10-Year Power Purchase Agreement With U.S.-based Technology Company

Mizuho analyst Ben Chaiken maintains Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) with a Outperform and raises the price target from $222 to $227.

Price Target

Analyst Ratings

Mizuho Maintains Outperform on Vail Resorts, Raises Price Target to $227

<ul>
<li>Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancer</li>
<li>With a median follow-up of 12 months, median progression-free survival (PFS) has not been reached</li>
<li>6-month PFS rate was 73% in all patients, 81% in patients with ESR1 mutations, 70% in ESR1 wild-type patients, and 68% in patients with prior CDK4/6 inhibitor treatment; data continue to mature</li>
</ul>

Biotech

Health Care

General

OLMA

Olema Pharmaceuticals Announced Updated Results From The Ongoing Phase 1b/2 Study Of Palazestrant Combined With Ribociclib, In Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Or Metastatic Breast Cancer

ASGN

ASGN's ECS Lands $96M ARPA-H Contract To Enhance Biotechnology, Neuroscience, And Regenerative Medicine Initiatives

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) with a Buy and maintains $57 price target.

Reiteration

RIGL

HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target

As part of uniQure's Regenerative Medicine Advanced Therapy (RMAT) Type B meeting held in late November, the FDA agreed that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway, avoiding the need for an additional pre-submission study.&nbsp;
The FDA also agreed that cUHDRS may be used as an intermediate clinical endpoint and that reductions in neurofilament light chain (NfL) measured in cerebrospinal fluid (CSF) may serve as supportive evidence of therapeutic benefit in the application for accelerated approval.

QURE

uniQure Reaches Agreement With FDA On Key Elements Of An Accelerated Approval Pathway For AMT-130

Donald Trump humorously referred to Canadian Prime Minister Justin Trudeau as &#8220;Governor&#8221; in a post on Tuesday. Trump mentioned a recent dinner with Trudeau, calling him the &#8220;Governor of the Great State of Canada.&#8221; 
What Happened: The post followed discussions on tariffs and trade between the two leaders during a high stakes dinner last Friday. Trump expressed enthusiasm about future meetings, stating that the results of their talks would be &#8220;truly spectacular for all.&#8221;
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/10065030/Screenshot-2024-12-10-at-5.20.11%E2%80%AFPM-1024x618.png" alt="" class="wp-image-685010" style="width:823px;height:auto" /></figure>
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42380711/msnbcs-hayes-says-proposed-bill-could-transfer-100b-to-bitcoin-owners?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">MSNBC&#8217;s Hayes: Proposed Bill Could Transfer $100B From Taxpayers To Bitcoin Owners</a>
Trump&#8217;s post comes amid ongoing discussions about potential economic impacts of these tariffs. Economists and trade experts have raised concerns about the possible consequences for both Canadian and American markets.
Why It Matters: The lighthearted reference to Trudeau as &#8220;Governor&#8221; <a href="https://www.benzinga.com/news/global/24/12/42300450/trump-told-trudeau-canada-could-avoid-tariffs-by-becoming-51st-state-a-look-at-sectors-trade-war-could-impact">follows Trump&#8217;s suggestion</a> that Canada could avoid tariffs by becoming the 51st state. This idea, although not serious, highlights the tension surrounding the proposed tariffs. Several Canadian sectors could be affected by the tariffs, raising concerns among businesses.
Trudeau raised his concerns during the dinner last Friday, warning that the <a href="https://www.benzinga.com/media/24/11/42252924/canadian-pm-justin-trudeau-warns-trumps-25-tariff-plan-will-hurt-americans-at-high-stakes-dinner">tariffs would raise the prices </a>for Americans and will hurt American enterprises. 
Economists have warned that Trump&#8217;s tariffs on Canada, Mexico, and China could lead to higher costs for American consumers. These tariffs might increase <a href="https://www.benzinga.com/personal-finance/24/12/42367505/economists-warn-trumps-tariffs-on-canada-mexico-and-china-could-hurt-your-budget-more-than-help-it">prices on essential goods</a>, impacting household budgets. The humorous tone of Trump&#8217;s tweet contrasts with the serious economic implications of the proposed tariffs.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42378618/musk-fuels-speculation-on-us-bitcoin-reserve-as-crypto-surges?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Musk Fuels Speculation On US Bitcoin Reserve As Crypto Surges</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

Politics

Trump Humorously Calls Justin Trudeau As 'Governor' Days After Floating Idea Of Canada Dodging Tariffs As 51st State Of America

IN8bio, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced updated data from the ongoing Phase 1 trial of INB-100, an allogeneic, haploidentical gamma-delta T cell therapy in older patients with hematologic malignancies undergoing haploidentical stem cell transplant (HSCT) with reduced intensity conditioning (RIC) at the 2024 American Society of Hematology (ASH) Annual Meeting, being hosted in San Diego, CA.

INAB

IN8bio Reports No New Deaths or Relapses in Phase 1 Trial of Gamma-Delta T Cell Therapy

Mizuho analyst Vijay Rakesh maintains Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) with a Neutral and raises the price target from $15 to $17.

MBLY

Mizuho Maintains Neutral on Mobileye Global, Raises Price Target to $17

Fiscal 2025
Net sales are expected to increase by approximately 2% to approximately $3.15 billion (prior approximately $3.20 billion), compared to net sales of $3.10 billion for fiscal 2024.
Net income is expected to be between $185.0 million and $190.0 million (prior $179.0 million and $184.0 million), or diluted earnings per share between $4.08 and $4.18 (prior $3.94 and $4.04). This compares to net income of $176.2 million, or $3.75 per diluted share, for fiscal 2024.
Non-GAAP net income for fiscal 2025 is expected to be between $186.0 million and $191.0 million (prior $180.0 and $185.0 million), or diluted earnings per share between $4.10 and $4.20 (prior $3.95 and $4.05). This compares to non-GAAP net income of $189.8 million, or diluted earnings per share of $4.04 for fiscal 2024.
Adjusted EBITDA for fiscal 2025 is expected to be between $309.0 million and $314.0 million (prior $305.0 million and $310.0 million) compared to adjusted EBITDA of $324.1 million in fiscal 2024.
Net interest expense is expected to be approximately $20.4 million, including a $1.6 million non-GAAP charge related to the write-off of deferred financing costs associated with the redemption of the Notes.
We estimate a tax rate of 28.6% for fiscal 2025.

Earnings

Guidance

GIII

G-III Apparel 2025 Outlook, Updated: Now Sees Net Sales Of $3.15B (Prior $3.20B) Vs. $3.20B Estimate And Adjusted EPS Of $4.10-$4.20 (Prior $3.95-$4.05) Vs. $4.02 Est.

J.M. Smucker Highlights Transformed Portfolio At 2024 Investor Day; Says Highly Confident In Its Ability To Deliver Long-term Algorithm, Including  Goal Of Over $1B In Free Cash Flow Annually

Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.32 by 59.38 percent. The company reported quarterly sales of $80.162 million which missed the analyst consensus estimate of $81.947 million. This is a 100.00 percent decrease over sales of $84.076 million the same period last year.

Earnings Misses

VNCE

Vince Holding Q3 2024 Adj. EPS $0.13 Misses $0.32 Estimate, Sales $80.162M Miss $81.947M Estimate

JP Morgan analyst Michael Cho initiates coverage on Stifel Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) with a Neutral rating and announces Price Target of $120.

Initiation

JP Morgan Initiates Coverage On Stifel Financial with Neutral Rating, Announces Price Target of $120

UNFI

United Natural Foods Expects 2025 Net Sales Of $0.40-$0.80 Compared To Prior Guidance Of $0.20 - $0.80 And Consensus Of $0.55

American EV giant Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) China sales are picking up momentum despite trailing behind Chinese EV maker BYD Co Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>).
What Happened: Insurance registrations for Tesla vehicles in China came in at 21,900 units for the week that ended on December 8, marking its second-best week in 2024, according <a href="https://cnevpost.com/2024/12/10/china-ev-insurance-registrations-week-ending-dec-8-2024/">to</a> a report by CnEVPost.
The week prior to that, the company had just 18,700 registrations.
Tesla&#8217;s Chinese competitor BYD, meanwhile, had 85,000 registrations, down 13.09% from the week before. BYD, unlike Tesla, makes both battery electric vehicles and plug-in hybrids.
EV startup Li Auto is following Tesla close on heels with weekly registrations touching 12,600 last week. China&#8217;s newest EV entrant, Xiaomi, also had 5,400 insurance registrations last week. Insurance registrations in China are considered a proxy for sales.
Analyst Take: Tesla Bull and The Future Fund Managing Partner Gary Black deems the latest insurance registration numbers &#8220;outstanding.&#8221;
&#8220;Tesla China reported an outstanding 21,900 insured registrations for the week of Dec 2-8. This was the 2nd highest week of the year, and 3rd highest week ever. With 3 weeks left in the quarter, 4Q is +17.8% YoY and +9.5% QoQ,&#8221; Black noted.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> China reported an outstanding 21,900 insured registrations for the week of Dec 2-8. This was the 2nd highest week of the year, and 3rd highest week ever. With 3 weeks left in the quarter, 4Q is +17.8% YoY and +9.5% QoQ. Separately, China BEV adoption reached a record… <a href="https://t.co/AozafLf7Hj">pic.twitter.com/AozafLf7Hj</a>
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1866360544648728683?ref_src=twsrc%5Etfw">December 10, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Tesla CEO Elon Musk also applauded the team in China for the achievement. &#8220;Great work by Tesla China,&#8221; he said in a post on social media platform X. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Great work by Tesla China
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1866326149904879948?ref_src=twsrc%5Etfw">December 10, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters:&nbsp;Tesla has to deliver at least 514,926 EVs globally in the last quarter if it is to beat its 2023 delivery number of nearly 1.81 million. China is Tesla&#8217;s&nbsp;<a href="https://www.benzinga.com/news/24/06/39393504/tesla-rolls-out-upgraded-model-3-performance-to-chinese-customers" target="_blank" rel="noreferrer noopener">second-largest market&nbsp;</a>after the U.S., making deliveries in the region key to realizing Tesla's annual delivery goal.
However, Tesla has never managed to deliver over 500,000 EVs in a quarter to date, making this an&nbsp;<a href="https://www.benzinga.com/tech/24/11/41894615/tesla-q4-deliveries-expected-to-set-new-records-but-not-enough-to-avoid-yearly-sales-decline-says-researcher" target="_blank" rel="noreferrer noopener">ambitious target.</a>
In the third quarter, Tesla reported deliveries of 462,890 vehicles, up 6.4% year-over-year and up 4.3% quarter-over-quarter.
Deliveries fell 8.5% year-on-year in the first quarter and by 4.8% in the second quarter.
Price Action:&nbsp;Tesla shares closed up 0.15% at $389.79 on Monday. Year-to-date, the stock has gained 56.9%, according to&nbsp;<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42405564/tim-kuniskis-to-return-to-lead-ram-trucks-days-after-stellantis-ceos-departure-report">Tim Kuniskis To Return To Lead Ram Trucks Days After Stellantis CEO&#8217;s Departure: Report</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

BYDDF

BYDDY

TSLA

Tesla's 2nd Best Week in China In 2024 Boosts Q4 Prospects

Needham analyst Mike Cikos maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Buy and raises the price target from $335 to $415.

Needham Maintains Buy on MongoDB, Raises Price Target to $415

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.yelp.com%2F&amp;esheet=54164509&amp;newsitemid=20241210611703&amp;lan=en-US&amp;anchor=Yelp+Inc.&amp;index=1&amp;md5=4f7f6f52c6a0c31b231e4625ec12af41">Yelp Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>), the company that connects people with great local businesses, today announced its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fblog.yelp.com%2Fnews%2Fend-of-year-product-release-2024%2F&amp;esheet=54164509&amp;newsitemid=20241210611703&amp;lan=en-US&amp;anchor=end-of-year+product+release&amp;index=2&amp;md5=93207835eb18bd6e8edffd6af9d6932b">end-of-year product release</a> featuring more than 20 new updates designed to enhance the user experience for both consumers and business owners. Yelp's latest product release includes AI-driven features, such as Review Insights that surface reviewer sentiment for common topics, a personalized home feed with even more user content, and enhancements to <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fblog.yelp.com%2Fnews%2Fspring-product-release-2024%2F&amp;esheet=54164509&amp;newsitemid=20241210611703&amp;lan=en-US&amp;anchor=Yelp+Assistant&amp;index=3&amp;md5=c8ea96b25d478965f106fad3b91d5071">Yelp Assistant</a>, the AI chatbot that connects consumers with service pros. Yelp also announced AI-powered improvements to the business owner experience with features like job summaries that help manage their inbox and a smart selection tool that automatically optimizes ad performance.

Yelp Rolls Out Over 20 New Updates, Including AI Tools for Personalized Feeds and Ad Management

Fiscal 2025 Outlook (1)
The Company is increasing its full-year outlook for all metrics other than Capital and Cloud implementation expenditures:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Fiscal Year Ending August 2, 2025 (52 weeks)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Previous Full Year Outlook Provided October 1, 2024</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Updated Full Year Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net sales ($ in billions)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$30.3 - $30.8</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$30.6 - $31.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net loss ($ in millions)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$(41) - $(3)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$(31) - $(3)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">EPS (2)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$(0.65) - $(0.05)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$(0.45) - $(0.05)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS (2)(3)(4)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.20 - $0.80</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$0.40 - $0.80</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (4) ($ in millions)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$520 - $580</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$530 - $580</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital and cloud implementation expenditures (4)(5) ($ in millions)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~ $300</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~ $300</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free cash flow (6)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">~ $100</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&gt; $100</td>
</tr>
</tbody>
</table>
</figure>

United Natural Foods Expects 2025 Net Sales Of $30.6B-$31.0B Compared To Prior Guidance Of $30.3B-$30.8B And Consensus Of $30.723B

MoneyHero Q3 EPS $0.10, Sales $20.9M Up From $19.7M YoY

CervoMed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) ("CervoMed" or the "Company"), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies (DLB). The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes (CDR-SB) or any of its key secondary endpoints – change from baseline in Timed Up and Go (TUG) test, change from baseline in a Neuropsychological Test Battery (NTD) and the Clinician's Global Impression of Change (CGIC). Initial analysis shows that target plasma drug concentrations were not achieved during the double-blind phase of the trial, which may have adversely impacted trial results.

CRVO

CervoMed's Phase 2b Trial on Neflamapimod Fails to Meet Key Endpoints for Dementia Treatment

Western Acquisition Ventures Corp. (WAVS) has released an update. Western Acquisition Ventures Corp. has been notified by Nasdaq that it no longer ...

Western Acquisition Ventures Risks Nasdaq Delisting

Western Acquisition Ventures Corp. ( ($WAVS) ) has issued an announcement. Western Acquisition Ventures Corp. and Executive James P. McCormick have...

Western Acquisition Ventures Updates Executive Compensation Terms

Financing

Press Releases

Western Acquisition Ventures Corp. Received Expected Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

Western Acq Ventures

Comments

Western Acq Ventures

Western Acq Ventures (WAVS) Forecast

Western Acq Ventures (NASDAQ:WAVS) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga